PHARMACOKINETICS OF ORG NC45 (NORCURON) IN PATIENTS WITH AND WITHOUT RENAL FAILURE

Publisher Website
Google Scholar
Abstract
To determine the influence of renal failure on the pharmacokinetics and neuromuscular blockade of Org NC45 (Norcuron), a new monoquaternary homologue of pancuronium, 13 patients under halothane and nitrous oxide anesthesia were studied. Org NC45 was administered by 2 min infusion in doses of 0.28 mg/kg (normal renal function group = 4) and 0.14 mg/kg (renal failure group, 5). Four additional patients with normal renal function were given Org NC45 0.14 mg/kg to determine the onset, duration and recovery rate of neuromuscular blockade. The serum concentration of Org NC45 was determined by normal-phase high performance liquid chromatography (sensitivity 50 ng/ml), and a 2-compartment open pharmacokinetic model was fitted to resulting data. Estimates of distribution half-life, elimination half-life, volume of distribution at steady state and clearance of Org NC45 did not differ significantly between patients with normal renal function and those with renal failure. The onset, duration and recovery rate times of the neuromuscular blockade by Org NC45 0.14 mg/kg in patients with normal renal function and those with renal failure also did not differ significantly.